<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587103</url>
  </required_header>
  <id_info>
    <org_study_id>2016-I2M-1-006-2</org_study_id>
    <nct_id>NCT03587103</nct_id>
  </id_info>
  <brief_title>Learning Implementation of Guideline-based Decision Support System for Hypertension Treatment: Testing Alternative Antihypertensive Regimens Using ACE-Inhibitors, Calcium Channel Blockers and Diuretics (LIGHT-ACD)</brief_title>
  <official_title>Learning Implementation of Guideline-based Decision Support System for Hypertension Treatment: Testing Alternative Antihypertensive Regimens Using ACE-Inhibitors, Calcium Channel Blockers and Diuretics (LIGHT-ACD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial aims to compare the efficacy of several guideline-based hypertensive medication
      regimens initiated with Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker
      [A], Calcium Channel Blocker [C] and Diuretic [D].
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The LIGHT-ACD Trial is conducted based on the LIGHT trial and aims to compare the efficacy of
      several guideline-based hypertensive medication regimens initiated with A, C and D for BP
      control.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average change in BP from first visit after the decision support system is installed to 9-month among the individuals who initiated with A, C, and D (population 1) and among those who initiated with two-drug therapy with AC, AD or CD (population 2)</measure>
    <time_frame>Baseline; 1 year</time_frame>
    <description>Average change in BP from first visit after the decision support system is installed to 9-month among population 1 (SBP 140-159 mmHg, not currently taking any antihypertensive medications) who initiated with A, C, and D and among population 2 (SBP≥160 mmHg, taking 0-1 antihypertensive medications which is not B; or SBP 140-159mmHg, taking one antihypertensive medication which is not B) who initiated with two-drug therapy with AC, AD or CD, respectively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of individuals with BP&lt;140/90 mmHg at 9 month.</measure>
    <time_frame>Baseline; 1 year</time_frame>
    <description>Proportion of individuals with BP&lt;140/90 mmHg at 9 month among the individuals (population 1: SBP 140-159 mmHg, not currently taking any antihypertensive medications) who initiated with A, C, and D, among those (population 2: SBP≥160 mmHg, taking 0-1 antihypertensive medications which is not B; or SBP 140-159mmHg, taking one antihypertensive medication which is not B) who initiated with two-drug therapy with AC, AD or CD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of individuals with BP&lt;160/100 mmHg at 9 month.</measure>
    <time_frame>Baseline; 1 year</time_frame>
    <description>Proportion of individuals with BP&lt;160/100 mmHg at 9 month among the individuals (population 1: SBP 140-159 mmHg, not currently taking any antihypertensive medications) who initiated with A, C, and D, among those (population 2: SBP≥160 mmHg, taking 0-1 antihypertensive medications which is not B; or SBP 140-159mmHg, taking one antihypertensive medication which is not B) who initiated with two-drug therapy with AC, AD or CD separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of individuals who received monotherapy, two-drug treatment, three-drug treatment, or referral at 9 month.</measure>
    <time_frame>Baseline; 1 year</time_frame>
    <description>Proportion of individuals who received monotherapy (only in populations 1), two-drug treatment, three-drug treatment, or referral at 9 month among the individuals (population 1: SBP 140-159 mmHg, not currently taking any antihypertensive medications) who initiated with A, C, and D, among those (population 2: SBP≥160 mmHg, taking 0-1 antihypertensive medications which is not B; or SBP 140-159mmHg, taking one antihypertensive medication which is not B) who initiated with two-drug therapy with AC, AD or CD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of individuals intolerant to each of the four medications.</measure>
    <time_frame>Baseline; 1 year</time_frame>
    <description>Proportion of individuals intolerant to each of the four medications among the individuals (population 1: SBP 140-159 mmHg, not currently taking any antihypertensive medications) who initiated with A, C, and D, among those (population 2: SBP≥160 mmHg, taking 0-1 antihypertensive medications which is not B; or SBP 140-159mmHg, taking one antihypertensive medication which is not B) who initiated with two-drug therapy with AC, AD or CD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of individuals who switched to usual care for any reason.</measure>
    <time_frame>Baseline; 1 year</time_frame>
    <description>Proportion of individuals who switched to usual care for any reason among the individuals (population 1: SBP 140-159 mmHg, not currently taking any antihypertensive medications) who initiated with A, C, and D, among those (population 2: SBP≥160 mmHg, taking 0-1 antihypertensive medications which is not B; or SBP 140-159mmHg, taking one antihypertensive medication which is not B) who initiated with two-drug therapy with AC, AD or CD.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison of average change in BP from the first visit after randomization to 9-month between A-AC-ACD and A-AD-ADC, C-CA-CAD and C-CD-CDA, and D-DA-DAC or D-DC-DCA only in population 1, respectively.</measure>
    <time_frame>Baseline; 1 year</time_frame>
    <description>Comparison of average change in BP from first visit after randomization to 9-month between protocol A-AC-ACD and A-AD-ADC, C-CA-CAD and C-CD-CDA, and D-DA-DAC or D-DC-DCA among population 1(SBP 140-159 mmHg, not currently taking any antihypertensive medications) .</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Protocol initiate with A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will be randomized to receive one of the protocols initiated with A, or the protocols initiated with two-drug combination therapy with full dose A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocol initiate with C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will be randomized to receive one of the protocols initiated with C, or the protocols initiated with two-drug combination therapy with full dose C.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Protocol initiate with D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will be randomized to receive one of the protocols initiated with D, or the protocols initiated with two-drug combination therapy with full dose D.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Protocol initiate with A</intervention_name>
    <description>The BP-lowering medication adjustment and titration will follow A-AC-ACD or A-AD-ADC for individuals randomized to A or two-drug combination therapy with full dose of A in their initial medication assignment.</description>
    <arm_group_label>Protocol initiate with A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Protocol initiate with C</intervention_name>
    <description>The BP-lowering medication adjustment and titration will follow C-CA-CAD or C-CD-CDA for individuals randomized to C or two-drug combination therapy with full dose of C in their initial medication assignment.</description>
    <arm_group_label>Protocol initiate with C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Protocol initiate with D</intervention_name>
    <description>The BP-lowering medication adjustment and titration will follow D-DA-DAC or D-DC-DCA for individuals randomized to D or two-drug combination therapy with full dose of D in their initial medication assignment.</description>
    <arm_group_label>Protocol initiate with D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Age ≥18 years

          2. Local resident of the community/township who attend a PHC center with DSS treatment of
             hypertension

          3. Established diagnosis of essential hypertension, with SBP≥140mmHg and &lt;180mmHg

          4. Not currently taking any antihypertensive medication or taking only one
             antihypertensive medication which in not B

        Exclusion criteria:

          1. History of coronary heart disease (i.e., angina, MI, CABG, PCI, &gt;50% stenosis of
             coronary artery, or positive stress test)

          2. Physician-diagnosed or self-reported CKD, eGFR &lt;60 mL/min/1.73m2 (if serum creatinine
             available), or currently on dialysis

          3. Physician-diagnosed diabetes mellitus

          4. Physician-diagnosed heart failure

          5. Physician-diagnosed secondary hypertension

          6. Intolerance to any class of antihypertensive medications among A, C or D

          7. Other serious medical illness such as malignant cancer, hepatic dysfunction, et al.

          8. Currently at the acute phase of any diseases

          9. Subject is pregnant or breast feeding, or planning to become pregnant or breast
             feeding during study period

         10. Patients measured blood pressure at home and the average self-measured home blood
             pressure &lt;135/85mmHg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Zheng, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>China National Center for Cardiovascular Disease</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin Zheng, MD, PhD</last_name>
    <phone>+86 60866813</phone>
    <email>xin.zheng@fwoxford.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Harlan Krumholz, MD, SM</last_name>
    <phone>+86 60866813</phone>
    <email>harlan.krumholz@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Luoyang Oriental hospital</name>
      <address>
        <city>Beijing</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yankuang Hospital</name>
      <address>
        <city>Zoucheng</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Zheng</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 3, 2018</study_first_submitted>
  <study_first_submitted_qc>July 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

